# Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

> **NCT02760056** · PHASE1 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 15 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Liothyronine sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02760056
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-06
- **Primary completion:** 2017-01-10
- **Final completion:** 2017-01-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760056, "Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02760056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*